Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 11.1% – Here’s What Happened

Ascendis Pharma A/S (NASDAQ:ASND) shares dropped 11.1% during mid-day trading on Tuesday . The stock traded as low as $234.12 and last traded at $235.6050. Approximately 288,955 shares traded hands during trading, a decline of 57% from the average daily volume of 667,871 shares. The stock had previously closed at $264.92.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis authorized a share repurchase program of up to $400 million. Although purchases are discretionary and may be modified or suspended, the program could support earnings per share and signal management’s confidence in the company’s financial position. Ascendis Announces Planned $400 Million Share Repurchase Program
• Positive Sentiment: Insider activity has been broadly supportive over the past six months, with nine purchases versus two sales. Institutional ownership was also mixed, but major investors including T. Rowe Price, BlackRock and State Street reported sizable additions.
• Neutral Sentiment: Ascendis will regain exclusive rights to its TransCon programs in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide for potential obesity and type 2 diabetes treatment. The move gives Ascendis greater control and potential long-term value, but the programs remain investigational and require further development, regulatory approval and funding. Ascendis to Regain Rights to TransCon Technology
• Negative Sentiment: The termination removes Novo Nordisk’s partnership support and leaves Ascendis responsible for development, manufacturing and commercialization. Investors appear concerned that Ascendis is losing near-term certainty and taking on greater execution, financial and regulatory risk.
• Negative Sentiment: A same-day Raymond James rating action reinforced the cautious reaction, even though several earlier analysts maintained bullish targets. The reported median 12-month target of approximately $326 remains above recent trading levels, but those targets may not yet fully reflect the partnership change. Raymond James Analyst Action

Analyst Upgrades and Downgrades

A number of research firms recently commented on ASND. BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Wedbush restated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Barclays decreased their price target on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Stifel Nicolaus lowered their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Citigroup assumed coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They set a “buy” rating and a $355.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $310.80.

Ascendis Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The firm’s 50 day simple moving average is $257.36 and its 200 day simple moving average is $242.38. The firm has a market capitalization of $14.50 billion, a price-to-earnings ratio of 18.03 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Sell-side analysts forecast that Ascendis Pharma A/S will post 3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé acquired 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Personal CFO Solutions LLC lifted its holdings in Ascendis Pharma A/S by 4.4% in the first quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 64 shares during the period. EverSource Wealth Advisors LLC boosted its position in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the biotechnology company’s stock worth $2,338,000 after purchasing an additional 112 shares during the period. Allworth Financial LP increased its holdings in shares of Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 122 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in shares of Ascendis Pharma A/S by 0.6% during the 4th quarter. Kennedy Capital Management LLC now owns 19,862 shares of the biotechnology company’s stock valued at $4,235,000 after purchasing an additional 123 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.